By Connor Hart
A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission.
The companies said Tuesday that the approval makes the therapy, lecanemab, the first of its kind to be granted a marketing approval in the European Union. The approval applies to all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
Lecanemab is indicated to treat certain adult patients with mild cognitive impairment and dementia due to Alzheimer's disease, the company said.
"The approval of lecanemab by the European Commission marks the thirteenth approval of this important medicine, which has already benefited thousands of patients in the United States, Japan and other regions of the world," Biogen Chief Executive Christopher Viehbacher said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 15, 2025 19:57 ET (23:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。